Published in Medical Letter on the CDC and FDA, May 23rd, 2004
The trial is being conducted by researchers at Georgetown University.
The study's enrollment at the outset is limited to 10 patients who are in virologic failure and no longer able to benefit from the administration of Highly Active Anti-Retroviral Therapy (HAART). It is estimated that more than 50% of AIDS patients ultimately become non-responsive to such drugs during the course of their...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA